Related Experiment Video
Updated: Mar 22, 2026

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
Published on: March 17, 2023
Mitochondrial Biogenesis Inhibitors for Anticancer Therapy: A Review of Recent Patents
Jinzheng Wang, Xiaoan Wen, Jun Liu1
1. junincpu@yahoo.com.
Abstract:
Recent studies show that enhanced mitochondrial biogenesis can "fuel" the cancer cells to grow and migrate. It is therefore proposed that inhibiting the mitochondrial biogenesis could be a new approach to cancer therapy. This review summarizes recent patents and papers in the development of small molecule inhibitors of key regulators responsible for tumor mitochondrial biogenesis, including PPARγcoactivator-1α(PGC-1α), PPARγcoactivator-1β, estrogen-related receptor family (ERRs), estrogen receptor α(ERα), mammalian target of rapamycin, c-Myc and PPARs.
Insights
Inhibiting mitochondrial biogenesis may offer a novel cancer therapy by starving cancer cells. This review covers small molecule inhibitors targeting key regulators of tumor mitochondrial growth.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Enhanced mitochondrial biogenesis fuels cancer cell growth and migration.
- Targeting cellular energy production presents a potential therapeutic strategy for cancer.
Purpose of the Study:
- To review recent patents and research on small molecule inhibitors of tumor mitochondrial biogenesis.
- To identify key regulators of mitochondrial biogenesis as therapeutic targets in cancer.
Main Methods:
- Literature review of scientific papers and patents.
- Focus on small molecule inhibitors targeting specific regulatory proteins.
Main Results:
- Identification of key regulators: PPARγcoactivator-1α (PGC-1α), PPARγcoactivator-1β, estrogen-related receptor family (ERRs), estrogen receptor α (ERα), mTOR, c-Myc, and PPARs.
- Summary of current developments in small molecule inhibitor research for these targets.
Conclusions:
- Inhibiting mitochondrial biogenesis is a promising avenue for cancer therapy.
- Development of small molecule inhibitors targeting key regulators shows potential for clinical application.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
07:58An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity
Published on: May 12, 2020
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Mitochondrial Precursor Proteins
Most of the mitochondrial...
Mitochondria
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies